Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

计划入组 602 人 · 首次发布于 2023 年 4 月 4 日

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

计划入组 600 人 · 首次发布于 2026 年 9 月 14 日

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

计划入组 800 人 · 首次发布于 2025 年 6 月 30 日

Puxitatug Samrotecan

Tilatamig samrotecan

AstraZeneca Advances Weight-Loss Drug Elecoglipron to Phase III as Company Targets $80B Revenue by 2030

Puxitatug Samrotecan Shows Promise in Advanced Endometrial Cancer with 38% Response Rate

AZD8205 Shows Promise in Heavily Pretreated Solid Tumors: ESMO 2024